Feb 7, 2018
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems. Read the full article here: biopharma-reporter.com
Feb 5, 2018
VANCOUVER, Wash., Feb. 5, 2018 /PRNewswire AbSci, announced the addition of Coherus Biosciences’ (NASDAQ: CHRS) Chief Scientific Officer, Alan Herman, PhD to its Scientific Advisory Board. Dr. Herman brings over 30 years of industry experience with expertise in...